Fighting the Host Reaction to SARS-COV-2 in Critically Ill Patients: The Possible Contribution of Off-Label Drugs

Stefania Scala* and Roberto Pacelli

1 Functional Genomics, Istituto Nazionale per lo Studio e la Cura dei Tumori, “Fondazione G. Pascale” – IRCCS, Naples, Italy, 2 Department of Advanced Biomedical Sciences, School of Medicine, University Federico II, Naples, Italy

The severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) is the etiologic agent of the 2019 coronavirus disease (COVID19). The majority of infected people present flu-like symptoms and among them 15–20% develops a severe interstitial pneumonitis (IP) that may eventually evolve in acute respiratory distress syndrome (ARDS). IP is caused by the viral glycoprotein spike (S) binding to the angiotensin converting enzyme 2 (ACE2) expressed on the surface of alveolar pneumocytes. The virus is recognized by the “pattern recognition receptors” (PRR) of the immune cells that release cytokines activating more immune cells that produce a large number of pro-inflammatory cytokines, tissue factors and vasoactive peptides. Affected patients might develop the “cytokine storm syndrome,” a fulminant and fatal hypercytokinaemia with multiorgan failure. In patients infected by SARS-COV-2 increase in T-helper 2 (TH2) cytokines (IL-4 and IL10) are reported in addition to the T-helper 1 (TH1) cytokines (IL1B, IFNγ, IP10, and MCP1) previously detected in other coronavirus infections. Cytokines and other molecules involved in immune response and inflammation are conceivable therapeutic targets for IP and ARDS, improving symptoms and decreasing intensive care unit admissions. To this aim off label drugs may be used taking into consideration the window timing for immunosuppressive drugs in virus infected patients. Some off label therapeutic options and preclinical evidence drugs are herein considered.

Keywords: cytokine, inflammation, offlabel drug use, macrophages, interstitial pneumonia

In December 2019 the third zoonotic coronavirus outbreak of this century happened in a cluster of Chinese patients most of which customers of a seafood market of Wuhan, a big city in the province of Hubei in China (1). On March 11th WHO officially declared a pandemic status. On May 7th, at the WHO website, 205 Countries, Areas, or Territories of the world with at least one case, a total of about 3,634,000 confirmed cases and more than 251,000 deaths were registered.

The severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) causing the corona virus disease of 2019 (COVID 19) is an about 30 kb single strand RNA beta-coronavirus characterized by a genetic mix originating from two bat and two human coronaviruses (Bat-SARS-like (SL)-ZC45, Bat-SL ZXC21, SARS-CoV, and MERS-CoV) (2). Although SARS-COV-2 is less lethal than SARS- and Middle East respiratory syndrome (MERS)-COV, the viral transmission efficiency is higher, with a supposed basic reproduction number of 2.24–3.58, and a mean incubation time of 6 days (3).
In a report on more than 70 thousands patients of the Chinese province of Hubei, the majority of infected symptomatic people presented flu like symptoms (mainly fever and cough), with 15–20% of patients developing a severe interstitial pneumonitis (IP) that could evolve in acute respiratory distress syndrome (ARDS). The case fatality rate in the whole population resulted 2.3% (8 and 15%, for patients older than 70 and 80, respectively). In critical patients 49% of case fatality rate was registered (4). IP is caused by the attack of the virus against the alveolar pneumocytes (APs) through the binding of the viral glycoprotein (spike, S) to the angiotensin converting enzyme 2 (ACE2) expressed on the surface of the APs (5). The virus enters in the host target cells through receptor-mediated endocytosis and quickly replicates; virus release in the extracellular space occurs through either budding or cell death. In the extracellular space the virus is recognized by the PRR of immune cells (6). This process contributes to the virus elimination through an amplification cascade in which the immune cells produce a large number of pro-inflammatory cytokines, tissue factors, and vasoactive peptides. These molecules reach the blood vessel wall causing a burst of nitric oxide, damages to the blood vessels and to the coagulation system (7). Among the most involved cells, macrophages play an important role in acute lung injury, which identify pathogen-associated molecular patterns (PAMP) and trigger innate immunity (8, 9). Macrophages secrete a large number of inflammatory mediators and cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin-1b (IL-1β), interleukin-6 (IL-6), inducible nitric oxide synthase (iNOS), and macrophage migration inhibitory factor (MIF). TNF-α can directly damage cells of the pulmonary vascular endothelium, increasing capillary endothelial permeability, causing pulmonary edema, predicted by IL-6 level (10). Progression to Acute Respiratory Distress Syndrome (ARDS) is based on the acute onset of lung inflammation, determined by monocyte/macrophage polarization and function. During active infection, inflammatory monocytes/macrophages (IMMs), and resident macrophages undergo marked phenotypic and functional changes, from M1 proinflammatory (classically activated) to M2 inflammatory-resolving macrophages, with a dynamic continuum through discrete categories. During acute infection, monocytes/macrophages often display a phenotype of classically activated macrophages that mediate antiviral host defenses but also promote lung injury by producing nitric oxide (NO), Reactive Oxygen Species (ROS), IL-1, IL-6, and IL-8 and TNF-α. Simultaneously, some macrophages may become M2 macrophages alternatively activated, exerting anti-inflammatory function and regulating wound healing by producing matrix metalloproteinases (MMPs), growth factors, and anti-inflammatory cytokines, particularly TGF-β. Pro-inflammatory macrophages diminish at the removal of stimulus (11–13).

Evidence of a cytokine storm has been found at the removal of severe pneumonitis linked to coronavirus infection (14). Previously, in patients with SARS, IL1β, IL6, IL12, IFNγ, IP10, and MCP1 were found to be increased (15). In patients with MERS, IFNγ, TNFα, IL15, and IL17 were shown to participate in the severity of the pneumonitis (16), and an elevated inflammatory innate immune response has been shown in the lower respiratory tract. Although those cytokines were elevated, down-regulation of genes encoding inflammatory TH1 and TH2 molecules was noted (17). Interestingly, in patients infected by SARS-CoV-2, there is an increase in IL1β, IFNγ, IP10, and MCP1, probably leading to activated T-helper-1 (TH1) cell responses, and increased production of T-helper-2 (TH2) immunosuppressive cytokines, such as IL4 and IL10 (18). In particular, a significant increase in IL2, IL7, IL10, G-CSF; IP10, MCP1/CC12, MIP1α, and TNFα was noted in patients requiring admission to the intensive care unit (ICU) compared to patients with a milder disease. As the infiltrate of monocytes, neutrophils, lymphocytes, and macrophages are the cellular actors of the inflammatory response (14), chemokine ligands and receptors play an important role in driving immune cell migration and homing (19). These cytokines may explain the observation of reduced levels of circulating lymphocytes. Peripheral blood examinations on admission in the majority of patients with COVID-19 displayed lymphopenia, elevated infection-related biomarkers (i.e., procalcitonin, erythrocyte sedimentation rate, serum ferritin, and C-reactive protein) (20) and several elevated inflammatory cytokines (i.e., tumor necrosis factor (TNF)-α, interleukin (IL)-2R and IL-6). Patients with more severe cases had higher leukocyte and neutrophil count, lower lymphocyte count and higher neutrophil-to-lymphocyte ratio (NLR) (21). Lymphocyte subsets showed that the total number of B cells, T cells and NK cells was significantly decreased in patients with COVID-19, more significantly so in severe cases. In particular, T cells (T helper, T suppressor, and Tregs cells) were mostly affected by SARS-CoV-2. In addition, recent evidence in SARS-CoV infection suggests that seroconversion may also play a role in lung injury. A detrimental role of early appearance of anti–spike (S)–IgG was demonstrated during SARS-CoV infection in a macaque model (22). Despite markedly reducing virus titers, anti–S-IgG caused lung injury during the early stages of infection, impairing the wound-healing macrophage response and TGF-β production, while promoting pro inflammatory cytokine IL-8, MCP1 production, and inflammatory macrophage accumulation (22). Interestingly, in SARS patients who died in Hong Kong during the 2002 outbreak, the anti–spike (S) glycoprotein neutralizing antibodies appeared significantly before and reached a higher titer than in patients surviving (23). Consistently, preexisting serum antibodies, derived by exposition to influenza seasonal strains, may recognize but fail to neutralize, the new pandemic strain and were found to associate with worse clinical severity during the 2009 influenza pandemic (24, 25).

The inflammatory status together with pulmonary edema and respiratory failure define the clinical picture of the ARDS associated with COVID-19 (26). The most compelling emergency that the health system faces in this epidemic is the shortage of critical care units. The saturation of intensive care units (ICU) precludes the rescue of patients who might be saved, increases COVID-19 lethality rate and worsens the prognosis for other pathological conditions requiring ICU admission. The severe IP or ARDS of the COVID-19 requires ventilator support and can kill infected people averaging in 2 weeks from the appearance of the first symptoms (27, 28). Therapy in use for HIV and
other viral disease have been empirically administered without much benefit (29), while promising experimental antiviral drugs such as remdesivir and chloroquine, an old antimalarial drug with in vitro activity on the viral infection, are currently in clinical trials (30, 31). In the absence of specific validated approaches, and waiting for a vaccine, a clinical empirical rational management is needed. Another reasonable approach would be drugs targeting the host immune-inflammatory reaction. Methylprednisolone, although somewhat controversial, seems to be overall useful in these patients (32), while dexamethasone has been shown to be useful in patients with ARDS of different etiologies (32, 33).

Cytokines and the other molecules involved in the immune response regulation and inflammation are conceivable targets to improve IP and ARDS lung injury. To this aim off label drugs may be used considering the timing for immunosuppressive drugs in virus infected patients. Unfortunately, the time window is not univocally defined and data may derive from clinical studies.

Several therapeutic options that could be rapidly translated to clinical trials are available. Some of them are listed below.

**TOCILIZUMAB**

Tocilizumab is an anti-IL6 receptor antibody (RoActemra, Roche) approved to treat moderate to severe rheumatoid arthritis (RA). Tocilizumab has been used to counteract the side effects of immune checkpoint inhibitors and CAR-T therapy in cancer bearing patients (34) and, recently, to antagonize the host reaction in patients affected by ARDS linked to COVID 19 (35). At today COVID-19 national management guidelines of Chinese health authorities include the use of Tocilizumab for severe pneumonia. A preliminary report on 21 critical cases of COVID-19 suggests efficacy of the treatment with faster recovery and lower risk of death for treated patients, while no toxicity was associated with the reported administration schedule (one or maximum two doses) (36). Timing of administration seems to be crucial as tocilizumab may be more efficient if administered earlier than actual use (37).

**ANAKINRA**

Anakinra is an interleukin-1 receptor antagonist (IL-1RA) previously evaluated in clinical trials for RA patients. IL-1beta/IL-1alpha are two stimulating cytokines of monocyte-macrophage cells acting upstream of the inflammatory signaling pathway induced by inflammasome, thus anakinra should block the cytokine storm. In a small open-label study, anakinra has been tested as agent preventive of mechanic ventilation in 9 patients hospitalized for moderate-severe COVID-19. Amelioration of oxygen flow and blood inflammation markers was described without significant toxicity (38). In clinically moderate and severe COVID-19 patients preliminary evidence reported high levels of three cytokines, CXCL10, CCL7 and IL-1, rather than IL-6, (39). In chronic use Anakinra could determine reaction at the site of injection and infection as the main side effects (40).

**EMAPALUMAB**

Emapalumab is a fully human IgG1 monoclonal antibody that binds free and receptor-bound interferon-γ. Emapalumab is approved by the US FDA for the treatment of haemophagocytic (HLH) (41) a rare disorder characterized by pathologic immune activation and hyperinflammation that eventually damage multiple organs. A prospective study has shown a good safety profile of emapalumab in pediatric and adolescent patients affected by HLH, with the infection susceptibility being the major threat (42). Blocking IFN γ activity could counteract the host immune hyper-reaction to SARS-COV-2.

**MYCOPHENOLATE**

Mycophenolic acid has been used as immunosuppressant agent in pemphigus as a corticosteroid-sparing agent and in kidney transplant patients to avoid rejection. It inhibits inositol monophosphate dehydrogenase, that causes depletion of guanosine and deoxyguanosine nucleotide pools impairing the activity of B and T lymphocytes. The drug has also been demonstrated to inhibit mRNA expression of pro-inflammatory cytokines TNF-α, IL-6, and IL-1β (43). Mycophenolic acid has been shown to have activity in vitro against zika virus replication (44) and coronavirus through a non-competitive inhibition of MERS-CoV papain-like protease (45). Urinary infections, diarrhea, and leukopenia are the side effects more often described (46).

**INFLIXIMAB AND ETANERCEPT**

Anti-TNFα agents used in autoimmune diseases, such as RA and ulcerative colitis, in principle, may have a role in treating severe respiratory syndrome of COVID-19. Infliximab is a monoclonal antibody targeting TNF alpha while Etanercept is a receptor fusion protein (Human IgG1-Fc plus soluble p75 TNF alpha extracellular domain). TNF-α is a proinflammatory cytokine produced by macrophages, lymphoid cells, endothelial cells, cardiac myocytes, adipose tissue, and brain cells such as microglia and astrocytes. Its receptors are widely expressed and TNF-α plays a key role in immunological defense processes such as inducing fever, inhibiting viral replication during infections, and leading to a permanent growth arrest in cancer (47, 48). Toxicity profile includes augmented risk of infections (49).

**PROTEASOME INHIBITORS**

Proteasomal system regulates different cell functions, among which nuclear factor kB (NF-kB) key transcription factor for innate and adaptive immunity (50). Bortezomib inhibits proteasome and it is used in the treatment of myeloma and mantle cell lymphoma. It has been shown to have antiviral activity against herpes virus, targeting viral entry, replication, and assembly (51). Another proteasome inhibitor, VR23, possess powerful anti-inflammatory activity reducing IL-6 in synovial cells from
RA patients, and improving LPS-induced acute lung injury by decreasing neutrophil migration, TNF-α secretion, and tissue inflammation in a mice model (52). The dose-limiting toxicity of proteasome inhibitors is the peripheral neuropathy (53) a clinically relevant complication, which negatively impacts the quality of life of multiple myeloma survivors (54).

PARP-INHIBITORS

Pandemic viruses decrease type I interferon (IFN) abundance (24). In humans 17 different types of poly-adenosine 5′-diphosphate (ADP)-ribose polymerase (PARP) are recognized. PARPs transfer ADP ribose from nicotinamide adenine dinucleotide (NAD+) to targeted proteins achieving a post translational modification called ADP-ribosylation, generally in response to stress conditions such as DNA damage, heat shock and viral attack (55). PARP11 is an ADP ribosyl-transferase that inhibits interferon type I (IFN-I) antiviral activity. IFN-I is a key component of the immune response against viral pathogens that induces the expression of several genes (Interferon Stimulated Genes –ISGs) with diverse antiviral properties (56). PARP11 inhibitor, rucaparib has been shown to restore the activity of IFN-I against different viruses in a murine model (57). There is evidence that ZIKV infection triggers type I IFN production by host cells, ZIKV is sensitive to the antiviral activity of IFN and IFN I seems crucial also in SARS-COV-2 infection (58, 59). PARP inhibitors are used in subgroup of patients with breast or ovarian cancer. Toxicity is mainly hematological (60).

PPARγ AGONISTS

Peroxisome proliferator-activated receptor gamma (PPARγ)-agonists, rosiglitazone and pioglitazone, are drugs in clinical use for diabetes (61). Insulin resistance amplifies inflammation, associated with an increase in C-reactive protein, IL-6, and TNF-α (62) and produces a pro-coagulant state with increased fibrinogen and plasminogen activator inhibitor, (PAI-1) (63). Pioglitazone, in clinical studies on diabetic patients, was able to reduce the plasma level of different inflammatory factors among which CPR, IL-1, IL-6, and TNF-α (64). Thus, it is of great interest that pioglitazone can produce an anti-inflammatory effect also on lung inflammation and fibrosis (65). Considered the excellent tolerability, PPARγ agonists may be tested for amelioration of virus induced lung injuries.

PLERIXAFOR

Plerixafor is a CXCR4 antagonist used for stem cell mobilization in patients undergoing autologous stem cell transplantation. CXCR4-mediated inflammatory responses is based on the efficient chemotaxis function of inflammatory cells, such as neutrophils, lymphocytes, and monocytes (66).

In murine models of acute lung insufficiency CXCR4 expression was significantly increased in macrophages sorted from bronchoalveolar lavage fluid and receptor downregulation reduced IL-6 and TNF-α. Administration of AMD3100 significantly attenuated the influx of inflammatory cells to the airway and reduced the levels of IL-4, IL-5, and IL-13 in an murine asthmatic model either in the lavage fluid and lung homogenate through attenuation of the Th17 (67), cell population. No adverse events have been described for a single injection of plerixafor (68).

SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTORS AGONISTS

Fingolimod, a sphingosine-1-phosphate (S1p) receptor agonist is approved for the treatment of multiple sclerosis (MS). S1p is mainly expressed in vascular endothelial cells and lymphocytes in lung tissue. S1p1 agonists (CYM-5442 and RP-002) have been reported to protect mice from death caused by severe influenza infection, attenuating cytokine production and inhibiting infiltration of innate immune cells. In a mouse model of 2009 H1N1 pandemic influenza, the S1p1 receptor agonist significantly inhibited synthesis of IL-1α, IL-1β, IL-6, IL-10, MCP-1, TNF-α, and GM-CSF, and reduced deaths from lethal infections by more than 80%. In addition the combination of oseltamivir can reduce mouse mortality by 96% (69). Recently a Multiple sclerosis (MS) patient in treatment with fingolimod that was diagnosed with COVID-19 reported a favorable outcome (70). As reported, the toxicity profile even for long term use, is reassuring (71).

In conclusion, while specific antiviral therapies are in rapid development (remdesivir, chloroquine, vaccine), controlling the powerful inflammatory response causing severe IP or ARDS is a reasonable approach. Agents that are available now to improve the lung injuries due to the host reactions and reduce the lethality of the disease are badly needed, and some are already in clinical studies. Drugs targeting multiple cyto/chemokines involved in SARS-COV-2 IP are available for trial or for off-label use, but close attention is needed to the schedule of administration, considered the immunosuppressive action of these drugs. To this aim rapid identification of prognostic factors in the peripheral immune profile may support therapeutic approach. Careful clinical studies are warranted.

AUTHOR CONTRIBUTIONS

SS and RP both equally contributed in designing and realizing the manuscript.
REFERENCES

1. Hui DS, Azhar EI, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health: The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. (2020) 91:264-6. doi: 10.1016/j.ijid.2020.01.009

2. Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. (2020) 92:418–23. doi: 10.1002/jmv.25681

3. Lai CC, Shih TP, Ko WC, Tang HJ, Hsieh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. (2020) 55:105924. doi: 10.1016/j.ijantimicag.2020.105924

4. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA. (2020). doi: 10.1001/jama.2020.2648. [Epub ahead of print]

5. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. (2020) 46:586–90. doi: 10.1007/s00134-020-05985-9

6. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. (2020) 395:1033–4. doi: 10.1016/S0140-6736(20)30628-0

7. Chosserman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol. (2017) 39:517–28. doi: 10.1007/s00281-017-0639-8

8. Aggarwal NR, King LS, D’Alessio FR. Diverse macrophage populations mediate acute lung inflammation and resolution. Am J Physiol Lung Cell Mol Physiol. (2014) 306:L709–25. doi: 10.1152/ajplung.00341.2013

9. Liu H, Zhou K, Liao L, Zhang T, Yang M, Sun C. Lipoxin A4 receptor agonist BML-111 induces autophagy in alveolar macrophages and protects from acute lung injury by activating MAPK signaling. Respir Res. (2018) 19:243. doi: 10.1186/s12931-018-0937-2

10. Zhou S, Wang G, Zhang W. Effect of TLR4/MyD88 signaling pathway on innate immune response in the lower respiratory tract. Cytokine. (2018) 104:8–13. doi: 10.1016/j.cyto.2018.01.025

11. Aloisami B, Hamed ME, Naeem A, Alshareef AA, AlQahtani SY, AlDosari KM, et al. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine. (2018) 102:176–80. doi: 10.1016/j.cyto.2018.06.018

12. Sarris M, Masson JB, Maurin D, Van der Aa LM, Boudinot P, Lortat-Jacob H, et al. Inflammatory chemokines direct and restrict leukocyte migration within live tissues as glycan-bound gradients. Curr Biol. (2012) 22:8375–82. doi: 10.1016/j.cub.2012.11.018

13. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. (2020) 63:364–74. doi: 10.1007/s11427-020-1643-8

14. Chen L, Liu HG, Liu W, Liu J, Liu K, Shang J, et al. [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]. Zhonghua Jie He He Xue Za Zhi. (2020) 43:203–8. doi: 10.7607/cma.j.issn.1001-0939.2020.03.013

15. Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok H, et al. Anti- spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. (2019) 4:1–19. doi: 10.1172/jci.insight.123158

16. Zhang L, Zhang F, Yu W, He Y, Yu J, CE, et al. Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals. J Med Virol. (2006) 78:1–8. doi: 10.1002/jmv.20499

17. Monsalvo AC, Bataille JP, Lopez MF, Krause JC, Klemenc JC, Hernandez JZ, et al. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat Med. (2011) 17:195–9. doi: 10.1038/nm.2262

18. To KK, Zhang AJ, Hung IF, Xu T, Ip WC, Wong RT, et al. High titer and avidity of nonneutralizing antibodies against influenza virus antigen are associated with severe influenza. Clin Vaccine Immunol. (2012) 19:1012–8. doi: 10.1128/CVI.00081-12

19. Sweeney RM, McAuley DF. Acute respiratory distress syndrome. Lancet. (2016) 388:2146–30. doi: 10.1016/S0140-6736(16)30578-X

20. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. (2020) 395:1054–62. doi: 10.1016/S0140-6736(20)30566-3

21. Peck TJ, Hibbert KA. Recent advances in the understanding and management of ARDS. F1000Res. (2019). doi: 10.2887/1000research.20111

22. Tao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. (2020) 382:1787–99. doi: 10.1056/NEJMoa2001282

23. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. (2020) 30:269–71. doi: 10.1038/s41422-020-0282-0

24. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical trials. Biosci Trends. (2020) 14:72–3. doi: 10.5582/bst.2020.01047

25. Wu C, Chen X, Cai Y, Xiao J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. (2020). doi: 10.1001/jamainternmed.2020.0994. [Epub ahead of print]

26. Villar J, Ferrando C, Martinez D, Ambros A, Munoz T, Soler JA, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. (2020) 8:267–76. doi: 10.1016/S2213-2600(19)30417-5

27. Amlani A, Barber C, Fiki-Mah A, Monzon J. Successful treatment of cytokine release syndrome with IL-6 blockade in a patient transitioning from immune-checkpoint to MEK/BRAF inhibition: a case report and review of literature. Oncologist. (2020). doi: 10.1634/theoncologist.2020-0194. [Epub ahead of print]

28. Chen C, Zhang XR, Ju ZY, He WF. [Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies]. Zhonghua Shao Shang Za Zhi. (2020) 36:1005. doi: 10.3760/cma.j.cn501120-20200224-00088

29. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. (2020) 117:10970–75. doi: 10.1073/pnas.2005615117

30. Michot JM, Albignes L, Chaput N, Saada V, Pommeret F, Griscelli F, et al. Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report. Ann Oncol. (2020). doi: 10.1016/annonc.2020.03.300. [Epub ahead of print]

31. Avoua A, Baldoli A, Geffray I, Verdon R, Bergot E, Martin-Silva N, et al. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series. Ann Rheum Dis. (2020). doi: 10.1136/annrheumdis-2020-217706. [Epub ahead of print].
39. Zhang Y, Zhong Y, Pan L, Dong J. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: are we already that far? Drug Discov Ther. (2020) 14:100–2. doi: 10.5382/ddt.2020.03006

40. Ramirez J, Canete JD. Anakinra for the treatment of rheumatoid arthritis: a safety evaluation. Expert Opin Drug Saf. (2018) 17:727–32. doi: 10.1080/14740338.2018.1486819

41. Al-Salama ZT. Emapalumab: first global approval. Drugs. (2019) 79:99–103. doi: 10.1007/s40265-018-1046-8

42. Locatelli F, Jordan MB, Allen C, Cesaro S, Rizzari C, Rao A, et al. Emapalumab in children with primary hematologic lymphohistiocytosis. N Engl J Med. (2020) 382:1811–22. doi: 10.1056/NEJMoa1911326

43. Balestri R, Rech G, Girardelli CR. Occurrence of SARS-CoV-2 during mycophenolate mofetil treatment for pemphigus. J Eur Acad Dermatol Venereol. (2020). doi: 10.1111/jdv.16578. [Epub ahead of print].

44. Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas J, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. (2020) 34:1. doi: 10.23812/JORH-E

45. To KKW, Mok KY, Chan ASF, Cheung NN, Wang P, Lui YM, et al. Al-Salama ZT. Emapalumab: first global approval. Drugs. (2019) 79:99–103. doi: 10.1007/s40265-018-1046-8

46. Hassan AV, Sinha MD, Waller S. A single-centre retrospective study of the potential conflict of interest. The authors declare that the research was conducted in the medical perspective of thiazolidine-2,4-dione: a remarkable scaffold in the treatment of type 2 diabetes. J Adv Res. (2020) 23:163–205. doi: 10.2337/jare.2020.01.008

47. Liu C, Feng X, Li Q, Wang Y, Li Q, Hua M. Adiponectin, TNF-alpha and inflammatory cytokines and risk of type 2 diabetes: a systematic review and meta-analysis. Cytokine. (2016) 86:1–17. doi: 10.1016/j.cyt.2016.02.028

48. King GL, Park K, Li Q. Selective insulin resistance and the development of cardiovascular diseases in diabetes: the 2015 edwin bierman award lecture. Diabetes. (2016) 65:1462–71. doi: 10.2337/db16-0152

49. Carbone E, Carta AR, Carbone E. Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19? Med Hypotheses. (2020) 140:109776. doi: 10.1016/j.mehy.2020.109776

50. Aoki Y, Maeno T, Aoyagi K, Ueno M, Aoki F, Aoki N, et al. Pioglitazone, a peroxisome proliferator-activated receptor gamma ligand, suppresses bleomycin-induced acute lung injury and fibrosis. Respiration. (2009) 77:311–9. doi: 10.1159/000106867

51. Tian X, Xie G, Xiao H, Ding F, Bao W, Zhang M. CXCR4 knockdown prevents inflammatory cytokine expression in macrophages by suppressing activation of MAPK and NF-kappaB signaling pathways. Cell Biol. (2019) 9:35. doi: 10.1186/s13578-019-0315-x

52. Chen H, Xu X, Teng J, Cheng S, Bunjhooh H, Cao Y, et al. CXCR4 inhibitor attenuates ovalbumin-induced airway inflammation and hyperresponsiveness by inhibiting Th17 and Th17 cell immune response. Exp Ther Med. (2016) 11:1865–70. doi: 10.3892/etm.2016.3141

53. Lagresle-Peyrou C, Lefrere F, Magrin E, Ribeil JA, Romano O, Weber L, et al. Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion. Haematologica. (2010) 95:778–86. doi: 10.3324/haematol.2017.184788

54. Oldstone MB, Teijaro JR, Walsh KB, Rosen H. Dissecting influenza virus pathogenesis uncovers a novel chemical approach to combat the infection. Virology. (2013) 435:92–101. doi: 10.1016/j.virology.2012.09.039

55. Banasz G, Thanikachalam PV, Maurya RK, Chawla P, Ramamurthy S. An overview on medicinal perspective of thiazolidine-2,4-dione: a remarkable scaffold in the treatment of type 2 diabetes. J Adv Res. (2020) 23:163–205. doi: 10.2337/jare.2020.01.008

56. Barzegar M, Mirmosayyeb O, Nehzat N, Sarrafi R, Khorvash F, Maghzi AH, et al. COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Neurol Neuroimmunol Neuroinflammm. (2020) 7. doi: 10.1212/NNIN.0000000000000753

57. Comi G, Hartung HP, Bakshi R, Williams IM, Wiendl H. Benefit-risk profile of sphingosine-1-phosphate receptor modulators in relapsing and secondary progressive multiple sclerosis. Drugs. (2017) 77:1755–68. doi: 10.1007/s40265-017-0814-1

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Scala and Pacelli. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.